Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease

The goal of this single-center prospective observational study is to identify and evaluate new biomarkers for ischemic cerebrovascular disease (ICVD) to aid in early diagnosis, individualized treatment planning, and prognosis prediction in affected patients. The main questions it aims to answer are: Can specific biomarkers help in identifying high-risk individuals before disease onset? Can these biomarkers predict disease progression and treatment response? Researchers will compare patients diagnosed with ICVD and healthy controls from a medical check-up center to assess differences in biomarker expression and their clinical significance. Participants will: Provide blood, cerebrospinal fluid, urine, and stool samples for biomarker analysis. Undergo clinical imaging (CT, MRI, PET-CT) and functional assessments. Be followed up at 3, 6, 12, 24, 36, and 48 months for clinical outcomes and biomarker changes. This study aims to develop a comprehensive biomarker-based prediction model to enhance the diagnosis and management of ischemic cerebrovascular disease.

NCT Number	NCT06890702
Lead Sponsor	Tongji Hospital
Conditions	Ischemic Stroke, Ischemic Cerebrovascular Disease
Enrollment	7,000 participants
Start Date	2025-01-01
Primary Completion	2035-12-27 (estimated)
Study Completion	2038-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-28